The four pillars of HFrEF therapy: is it time to treat heart failure regardless of ejection fraction?

The syndrome of heart failure (HF) has historically been dichotomized based on clinical trial inclusion criteria into patients with a reduced or preserved left ventricular ejection fraction (LVEF) using a cut-off of above or below 40%. The majority of trial evidence for the benefits of disease-modif...

Descripción completa

Detalles Bibliográficos
Autores principales: Docherty, Kieran F, Bayes-Genis, Antoni, Butler, Javed, Coats, Andrew J S, Drazner, Mark H, Joyce, Emer, Lam, Carolyn S P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
#GDMTWorks: The Race to Initiating and Optimizing HFrEF Therapies Supplement Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762881/
https://www.ncbi.nlm.nih.gov/pubmed/36545228
http://dx.doi.org/10.1093/eurheartjsupp/suac113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762881/
https://www.ncbi.nlm.nih.gov/pubmed/36545228
http://dx.doi.org/10.1093/eurheartjsupp/suac113

Ejemplares similares